Blog
Latest articles, insights, and updates from the blog.
FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality
The FDA has cleared the MIND1 trial testing NRX-101 plus robotic TMS for suicidality in treatment-resistant depression. What it means for ketamine patients.
CBT After Esketamine Cuts Relapse Risk, Trial Finds
The CBT-ENDURE trial shows 16 weeks of CBT after esketamine significantly reduces relapse risk and suicidal ideation. What it means for ketamine patients.
Esketamine Safety Protocols: What Clinicians Now Emphasize
A new clinical overview on esketamine nasal spray details REMS requirements, two-hour monitoring, and vitals tracking. Here's what it means for ketamine patients.
When to Switch or Stay: NMDA Therapy Discontinuation Rates
New analysis reveals why patients stop NMDA receptor antagonist therapy—and what discontinuation data means for low-dose ketamine monitoring and dosing decisions.
What Dropout Rates Reveal About NMDA Therapy Tolerability
New psychiatric guidance examines why patients stop NMDA antagonist therapy and what side effect data means for low-dose ketamine treatment decisions.
When Ketamine Side Effects Signal Time to Adjust Dose
New clinical analysis examines why patients stop NMDA antagonist therapy—and how smarter dose management may improve remission outcomes in TRD.
Faster TRD Remission Hinges on Measurement and Dose Timing
New analysis in Psychiatric Times shows that symptom tracking and rapid dose adjustment drive faster remission in TRD—here's what it means for ketamine care.
What Side Effect Data Tells Us About Ketamine Dosing
New analysis of NMDA receptor antagonist side effects in treatment-resistant depression underscores why dose optimization and early monitoring matter.
NMDA Antagonist Side Effects: What the Data Says
New clinical analysis examines why patients stop ketamine and esketamine treatment—and what smarter monitoring can do to keep them on track.
NRx FDA Review: Preservative-Free Ketamine Moves Forward
NRx Pharmaceuticals reports progress on its FDA application for preservative-free ketamine. Here's what the formulation difference means for low-dose patients.
Trump EO on Psychedelics: What It Means for Ketamine
President Trump's April 2026 executive order accelerating psychedelic research may reshape ketamine's regulatory and clinical landscape. Here's what we know.
NRx Moves Closer to FDA-Approved Preservative-Free Ketamine
NRx Pharmaceuticals signals FDA review progress on its preservative-free ketamine application. What this means for patients and clinicians in 2026.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.